Dietary Intervention for Cardiovascular Disease

October 25, 2023 updated by: Wen-Harn Pan, Academia Sinica, Taiwan
Incidence of cardiometabolic disease (CMD) continues to rise, which consumes huge medical resources in Taiwan. The effectiveness of dietary therapy for CMD has not been locally evaluated in detail. CVD is an important risk factor for dementia. At the present time, there is no effective treatment available for dementia. Early prevention is extremely important. Our previous studies have shown that Taiwanese dementia protective diet is very similar to cardiovascular prevention and control diet, meaning that effective dietary therapy may not only control CVD but also prevent dementia development. Therefore, this study intends to document the effects of dietary intervention on cardiovascular disease risk factor control, the long-term outcomes on the occurrence of cardiovascular events, and the maintenance of cognitive function for patients with coronary artery disease.

Study Overview

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beitou District
      • Taipei, Beitou District, Taiwan, 112
        • Taipei Veterans General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Have received percutaneous transluminal coronary artery surgery.
  2. Stable drug control for more than one month

Exclusion Criteria:

  1. Suffer from cancer and undergo chemotherapy or surgery within one year.
  2. Those who have a major illness in hospital within one year.
  3. Those with kidney disease stage 5 (inclusive) or above
  4. Those whose life expectancy does not exceed half a year
  5. Patients with diagnosed dementia
  6. Those who do not want to be tracked

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: usual medical management
with regular doctor visits every 3 months
with regular doctor visits every 3 months
Experimental: usual medical management+individual dietary consultation
with regular doctor visits every 3 months and dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit
with regular doctor visits every 3 months
with regular doctor visits every 3 months and dietitian visits every 3 months
Experimental: usual medical management+individual dietary consultation+ daily tea drinking
with regular doctor visits every 3 months, dietitian visits every 3 months until meeting dietary recommendation or reaching 3 years limit, and daily tea drinking
with regular doctor visits every 3 months
with regular doctor visits every 3 months and dietitian visits every 3 months
with regular doctor visits every 3 months and dietitian visits every 3 months and daily tea drinking

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in diet quality at Year 1, 2, and 3.
Time Frame: Baseline, year 1, 2 and 3

Diet quality is estimated according to the daily intake of nutrients and the distribution of the six food groups, with a qualified food frequency questionnaire.

The six food groups include:

  1. Whole grains and starchy vegetables
  2. Protein foods: soybeans, fish, eggs, and meat
  3. Vegetables
  4. Fruits
  5. Dairy
  6. Oils, nuts & seeds
Baseline, year 1, 2 and 3
Change from baseline in concentrations of cardiovascular risk factors at Month 6, 12, 18, 24,30, and 36.
Time Frame: Baseline and Month 6, 12, 18, 24, 30, and 36.
Cardiovascular risk factors include total cholesterol,triglyceride, low-density lipoprotein ,high-density lipoprotein, uric acid, glucose, HbA1C.
Baseline and Month 6, 12, 18, 24, 30, and 36.
Events of cardiovascular diseases at Year 6.
Time Frame: Year 6.
CVD or non-CVD death, stroke, acute myocardial infarction, hospitalization for acute coronary syndrome, hospitalization for coronary intervention surgery, hospitalization for various cardiovascular diseases, hospitalization for heart failure, hospitalization for other CVD diseases, new-onset heart arrhythmia, new-onset peripheral blood vessels block
Year 6.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in the dosage of prescribed drugs at Month 6, 12, 18, 24,30, and 36.
Time Frame: Baseline and Month 6, 12, 18, 24, 30, and 36.
Prescribed drugs for cardiovascular diseases.
Baseline and Month 6, 12, 18, 24, 30, and 36.
Change from baseline in cardiovascular risk score
Time Frame: Baseline, year 1, 2 and 3.
Taiwanese edition of Framingham Risk Score, a 10-year risk score derived as a percentage. Risk is considered low if the Framingham Risk Score is less than 10%, moderate if it is 10% to 19%, and high if it is 20% or higher.
Baseline, year 1, 2 and 3.
Change from baseline in concentrations of inflammatory markers at Year 1, 2, and 3.
Time Frame: Baseline, year 1, 2 and 3.
Inflammatory markers include IL-1β, IL-6, IL-8, IL-10,TNF- α, IFN-γ in blood.
Baseline, year 1, 2 and 3.
Change from baseline in scores of Montreal Cognitive Assessment at Year 1, 2, and 3.
Time Frame: Baseline, year 1, 2 and 3.
Scores on the Montreal Cognitive Assessment range from zero to 30. A score of 26 and higher is considered normal.
Baseline, year 1, 2 and 3.
Change from baseline in scores of Number Cancellation test
Time Frame: Baseline, year 1, 2 and 3.
A sub-scale of Alzheimer's Disease Assessment Scale. Cancellation score = number of targets hit in 45 seconds - (minus) number of errors - (minus) number of times reminded of the task.
Baseline, year 1, 2 and 3.
Change from baseline in the number of digits at Year 1, 2 and 3.
Time Frame: Baseline, year 1, 2 and 3.
A digit span task is used to measure working memory's number storage capacity. Subjects are read a sequence of numbers and asked to repeat the same sequence back to the examiner in order (forward span) or in reverse order (backward span). The score is the length of the longest correctly repeated sequence. The maximum number of digits in a sequence is 9 and the minimum number of digits in a sequence is 2. The higher scores mean a better outcome.
Baseline, year 1, 2 and 3.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Wen-Harn Pan, Ph.D, Institute of Biomedical Sciences, Academia Sinica

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 23, 2021

Primary Completion (Actual)

February 14, 2023

Study Completion (Actual)

February 14, 2023

Study Registration Dates

First Submitted

December 19, 2021

First Submitted That Met QC Criteria

January 7, 2022

First Posted (Actual)

January 21, 2022

Study Record Updates

Last Update Posted (Actual)

October 27, 2023

Last Update Submitted That Met QC Criteria

October 25, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AS-IRB-BM-19057

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on control:usual medical management

Subscribe